Michael Megally, MD
Pulmonary Disease · Rockville Ctr, NYNPI 1942549381
Payments from drug & device makers
Across 587 payments — averaging $73.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$35K
- Boehringer Ingelheim$2K
- AstraZeneca$1K
- Philips North America LLC$699
- Regeneron Healthcare Solutions, Inc.$606
- Sanofi$448
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$29,25068%
- Travel & lodging$8042%
- Food & beverage$12,57129%
- Education$2120%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 223 | $34,715 |
| Boehringer Ingelheim | 59 | $1,547 |
| AstraZeneca | 54 | $1,250 |
| Philips North America LLC | 45 | $699 |
| Regeneron Healthcare Solutions, Inc. | 22 | $606 |
| Sanofi | 20 | $448 |
| Grifols USA, LLC | 21 | $390 |
| Verona Pharma, Inc. | 18 | $305 |
| Amgen | 12 | $247 |
| Mylan Specialty L.p. | 11 | $247 |
| Harmony Biosciences LLC | 11 | $219 |
| Baxter Healthcare | 9 | $218 |
| Electromed, Inc. | 13 | $202 |
| Actelion Pharmaceuticals US, Inc. | 4 | $185 |
| Advanced Respiratory, Inc | 7 | $172 |
| Chiesi USA, Inc. | 5 | $167 |
| Inari Medical, Inc. | 1 | $140 |
| Mallinckrodt Hospital Products Inc. | 6 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Insmed, Inc. | 6 | $108 |
| AbbVie | 4 | $82 |
| Inogen, Inc. | 5 | $61 |
| Olympus America Inc. | 1 | $61 |
| Shionogi Inc | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Merck | 2 | $49 |
| Johnson & Johnson | 2 | $43 |
| Phadia US Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| 3b Medical, Inc. | 2 | $36 |
| Coaptech, Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Vapotherm Inc | 1 | $29 |
| Boston Scientific | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| ZOLL Respicardia, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$30,363
- SPIRIVA RESPIMAT$346
- FLOWTRIEVER CATHETER, S$140
- CT THROMBECTOMY SYSTEM KIT$140
- FASENRA$135
- TRELEGY ELLIPTA$120
How this compares
$42,855 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 55 | $690,316 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 283 | $362,654 |
| Dupixent PenDupilumab | 17 | $65,837 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $40,255 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $36,296 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $24,465 |
| XareltoRivaroxaban | 13 | $20,249 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $5,594 |
| Arnuity ElliptaFluticasone Furoate | 14 | $5,113 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,106 |
| DuleraMometasone/Formoterol | 13 | $4,181 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,648 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 15 | $1,111 |
| Fluticasone Propionate | 36 | $672 |
| Montelukast Sodium | 49 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $1,547 | $690,31655 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $34,715 | $437,593396 claims |
| AstraZenecaBreztri Aerosphere | $1,250 | $36,29630 claims |
| Johnson & JohnsonXarelto | $43 | $20,24913 claims |
| MerckDulera | $49 | $4,18113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Rockville Ctr
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.